Literature DB >> 24878619

Ceftriaxone-induced hemolytic anemia: case report and review of literature.

Michael S Northrop1, Hemant S Agarwal.   

Abstract

Ceftriaxone is a frequently used empiric antibiotic in children. Acute hemolysis is a rare side effect of ceftriaxone therapy associated with a high mortality rate. A 14-year-old boy suffering from Crohn disease developed bacterial pneumonia that was treated with ceftriaxone. We report successful management of ceftriaxone-induced hemolytic anemia (CIHA) in this patient and review the CIHA literature in pediatric patients. Early recognition of CIHA with prompt discontinuation of ceftriaxone therapy may have a beneficial role in reduction of high mortality seen in these patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 24878619     DOI: 10.1097/MPH.0000000000000181

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  5 in total

1.  No Evidence for Ceftobiprole-Induced Immune Hemolytic Anemia in Three Phase 3 Clinical Trials.

Authors:  Kamal Hamed; Tatiana Wiktorowicz; Maziar Assadi Gehr
Journal:  Infect Drug Resist       Date:  2020-09-16       Impact factor: 4.003

2.  When a transfusion in an emergency service is not really urgent: hyperhaemolysis syndrome in a child with sickle cell disease.

Authors:  Sara Chinchilla Langeber; Marta Pilar Osuna Marco; María Benedit; Áurea Cervera Bravo
Journal:  BMJ Case Rep       Date:  2018-03-27

3.  Ceftriaxone-Induced Hemolytic Anemia: A Rare Case Report.

Authors:  Sandeep Kumar; Rohit Bansal; Priya Bansal; Rajinder Kumar Dhamija; Dnb Neurology
Journal:  Perm J       Date:  2019-12-18

4.  Safety of ceftriaxone in paediatrics: a systematic review protocol.

Authors:  Linan Zeng; Imti Choonara; Lingli Zhang; Song Xue; Zhe Chen; Miaomiao He
Journal:  BMJ Open       Date:  2017-08-21       Impact factor: 2.692

Review 5.  Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature.

Authors:  Hans Benno Leicht; Elke Weinig; Beate Mayer; Johannes Viebahn; Andreas Geier; Monika Rau
Journal:  BMC Pharmacol Toxicol       Date:  2018-10-25       Impact factor: 2.483

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.